Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure

Mirjam B. Zeisel(Inserm), Julie Lucifora(Université Claude Bernard Lyon 1), William S. Mason(Fox Chase Cancer Center), Camille Sureau(Génomes, biologie cellulaire et thérapeutiques), Jürgen Beck(University Medical Center Freiburg), Massimo Levrero(Sapienza University of Rome), Michael Kann(Centre National de la Recherche Scientifique), Percy A. Knolle(Technical University of Munich), Monsef Benkirane(Centre National de la Recherche Scientifique), David Durantel(Université Claude Bernard Lyon 1), Marie-Louise Michel(Institut Pasteur), Brigitte Autran(Inserm), François‐Loïc Cosset(Université Claude Bernard Lyon 1), Hélène Strick‐Marchand(Inserm), Christian Trépo(Université Claude Bernard Lyon 1), Jia‐Horng Kao(National Taiwan University Hospital), Fabrice Carrat(Inserm), Karine Lacombe(Inserm), Raymond F. Schinazi(Emory University), Françoise Barré‐Sinoussi(Inserm), Jean-François Delfraissy(Agence Nationale de Recherches sur le Sida et les Hépatites Virales), Fabien Zoulim(Université Claude Bernard Lyon 1)
Gut
February 10, 2015
Cited by 272Open Access
Full Text

Abstract

HBV infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Although HBV infection can be efficiently prevented by vaccination, and treatments are available, to date there is no reliable cure for the >240 million individuals that are chronically infected worldwide. Current treatments can only achieve viral suppression, and lifelong therapy is needed in the majority of infected persons. In the framework of the French National Agency for Research on AIDS and Viral Hepatitis 'HBV Cure' programme, a scientific workshop was held in Paris in June 2014 to define the state-of-the-art and unanswered questions regarding HBV pathobiology, and to develop a concerted strategy towards an HBV cure. This review summarises our current understanding of HBV host-interactions leading to viral persistence, as well as the roadblocks to be overcome to ultimately address unmet medical needs in the treatment of chronic HBV infection.


Related Papers

No related papers found

Powered by citation graph analysis